Shopping Cart
- Remove All
Your shopping cart is currently empty
Fibronectin type III domain‑containing protein 1 (FNDC1) is a protein that contains a major component of the structural domain of fibronectin.FNDC1 was highly upregulated and acted as an oncogene in BC. Therefore, targeting FNDC1 may be a potential strategy for the treatment of BC.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 μg | $51 | 7-10 days | |
| 10 μg | $80 | 7-10 days | |
| 20 μg | $129 | 7-10 days | |
| 50 μg | $248 | 7-10 days | |
| 100 μg | $418 | In Stock | |
| 200 μg | $757 | 7-10 days | |
| 500 μg | $1,670 | 7-10 days |
| Biological Activity | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
| Description | Fibronectin type III domain‑containing protein 1 (FNDC1) is a protein that contains a major component of the structural domain of fibronectin.FNDC1 was highly upregulated and acted as an oncogene in BC. Therefore, targeting FNDC1 may be a potential strategy for the treatment of BC. |
| Species | Human |
| Expression System | E. coli |
| Tag | N-His |
| Accession Number | Q4ZHG4-1 |
| Synonyms | MEL4B3,KIAA1866,FNDC2 |
| Construction | Ala33-Thr457 |
| Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Molecular Weight | 48.68 kDa (predicted). The protein migrates to 50-55 kDa based on Tris-Bis PAGE result. |
| Endotoxin | < 1 EU/μg by the LAL method. |
| Formulation | Supplied as 0.22 μm filtered solution in 20 mM PB, 500 mM NaCl, 10% Glycerol. |
| Stability & Storage | It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Shipping | Shipping with blue ice. |
| Research Background | Fibronectin type III domain‑containing protein 1 (FNDC1) is a protein that contains a major component of the structural domain of fibronectin.FNDC1 was highly upregulated and acted as an oncogene in BC. Therefore, targeting FNDC1 may be a potential strategy for the treatment of BC. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.